GDUFA Public Hearing on Policy Development

On September 17, 2014, the Food and Drug Administration (FDA) hosted the public hearing on Policy Development to solicit public comment on the five draft guidance documents that were issued to facilitate implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA) and on future policy priorities, including recommendations for additional guidance topics to facilitate GDUFA implementation. FDA also requested feedback on issues that may arise in consideration of 180-day exclusivity provided for by paragraph IV patent certifications (section 505(j)(5)(b)(iv) of the Federal Food, Drug, and Cosmetic Act or FD&C Act). Finally, FDA requested feedback on the specific criteria FDA that should apply to identify an abbreviated new drug application (ANDA) as a first generic eligible for expedited ANDA review. On May 2, 2015, the FDA posted a Federal Register notice reopening the public docket for an additional 30 days in response to requests that FDA provide an additional opportunity to submit comments on these topics.

For more information and the latest events regarding GDUFA, please visit our Generic Drug User Fee Amendments of 2012 website.


Sign Up for Email Alerts about GDUFA


Page Last Updated: 12/16/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English